Stevanato Group (NYSE:STVN) Azioni

Stevanato Group

Stevanato Gr

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

Stevanato Group SpA

TD Securities analyst John Mould initiates coverage on Fortis (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FTS#TSX">FTS</a>) with a Buy rating and announces Price Target of C$74.

News

Price Target

Initiation

Analyst Ratings

TSX:FTS

TD Securities Initiates Coverage On Fortis with Buy Rating, Announces Price Target of C$74

Editor&#8217;s Note: The article has been updated to include comments from the office of Prime Minister Benjamin Netanyahu.
U.S. President&nbsp;Donald Trump and Israeli Prime Minister&nbsp;Benjamin Netanyahu&nbsp;are reportedly working on a plan to end the ongoing war in Gaza and expand the Abraham Accords, with new countries joining the peace agreement.
What Happened: The plan, as reported by&nbsp;Israel Hayom, would require Israel&nbsp;to commit to supporting a&nbsp;future Palestinian state. This proposal was discussed during a phone call between Trump and Israeli Prime Minister&nbsp;Benjamin Netanyahu&nbsp;on Monday, <a href="https://www.timesofisrael.com/netanyahu-trump-said-working-on-plan-to-end-gaza-war-and-expand-abraham-accords/">stated </a>The Times Of Israel. 
The leaders have reportedly agreed to bring the Gaza war to an end within a two-week timeline, which would require Israel to cease its military operations&nbsp;and Hamas to release the&nbsp;remaining 50 hostages. Following this, the leadership of the Palestinian group would be exiled, and the governance of the war-ravaged region would be jointly undertaken by four Arab nations, including the UAE and Egypt.
The plan also includes provisions for the rehabilitation of the Gaza Strip, absorption of Gazans wishing to emigrate by several undisclosed countries and Israel&#8217;s&nbsp;backing for a future two-state&nbsp;solution contingent on reforms&nbsp;by the Palestinian Authority. In&nbsp;exchange, Washington would acknowledge Israeli sovereignty over certain areas of the West Bank.
Once the war ends and Israel reaffirms its commitment to a two-state solution, Saudi Arabia and Syria are expected to establish diplomatic ties with Israel under the Abraham Accords, with other Arab and Muslim countries likely to follow.
Meanwhile, Netanyahu&#8217;s office <a href="https://www.columbusjewishnews.com/jns/pmo-denies-israel-us-talks-on-two-state-solution-took-place/article_45953d88-523b-547b-a1b0-4f46044e5a95.html">said</a>, &#8220;The conversation&#8230;did not take place." 
 "Israel was not presented with the political proposal supposedly described in the article, and it obviously did not agree to it."
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/health-care/25/06/46131597/bill-gates-says-he-knows-for-a-fact-that-more-children-will-die-due-to-us-health-aid-cuts-and-he" target="_blank" rel="noreferrer noopener">Bill Gates Says He Knows For A &#8216;Fact&#8217; That More Children Will Die Due To US Health Aid Cuts And He&#8217;s Taking The &#8216;Proof&#8217; To Congress</a>
Why It Matters: This development comes amid other significant events in the region. Trump recently&nbsp;urged Israel to cancel or pardon <a href="https://www.benzinga.com/news/politics/25/06/46108200/trump-calls-for-canceling-netanyahus-witch-hunt-corruption-trial-calls-it-a-travesty-of-justice">Netanyahu&#8217;s corruption</a> trial, calling it a &#8220;witch hunt.&#8221; This public support from Trump could have implications for the Israeli political landscape.
Meanwhile, U.S. Senator&nbsp;Elizabeth Warren&nbsp;recently&nbsp;<a href="https://www.benzinga.com/news/politics/25/06/46068097/elizabeth-warren-presses-marco-rubio-over-potential-500-million-usaid-diversion-to-controversial-gaza-foundation-report">raised concerns</a> about a proposal&nbsp;to redirect $500 million from USAID to the Gaza Humanitarian Foundation, a controversial organization. This proposal, if implemented, could have a significant impact on the humanitarian situation in Gaza.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://www.benzinga.com/news/politics/25/06/46132996/marco-rubio-says-everything-under-the-mountains-is-in-bad-shape-rubbishes-claim-trump-strikes-only-bought-iran-time">Marco Rubio Says &#8216;Everything Under The Mountains Is In Bad&#8217; Shape, Rubbishes Claim Trump Strikes Only Bought Iran Time</a> </li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump And Israel's Netanyahu Working On Plan To End Gaza War, Expand Abraham Accords: Report (UPDATED)

WIIM

ACHV

Achieve Life Sciences shares are trading lower after the company announced a $45 million public offering.

JMP Securities analyst Andrew Boone upgrades Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) from Market Perform to Market Outperform and maintains the price target from $220 to $220.

Upgrades

GOOGL

JMP Securities Upgrades Alphabet to Market Outperform, Maintains Price Target to $220

AEMD

Aethlon Medical shares are trading lower after the company reported a Q4 EPS miss.

BBLG

Bone Biologics shares are trading higher after the compnay announced it filed a USPTO patent for rhNELL-1.

Ainos, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMDW#NASDAQ">AIMDW</a>) ("Ainos" or the "Company") , a leader in AI-driven scent digitization, today announced the expansion of its strategic relationship with ASE Technology Holding Co., Ltd. ((", ASEH", , TWSE: 3711, NYSE:<a href="https://www.benzinga.com/stock/ASX#NYSE">ASX</a>), the world's leading provider of semiconductor assembly and test services. The two companies are contemplating a multi-phase roadmap to deploy Ainos' AI Nose platform across ASE's global manufacturing network, including facilities operated by Siliconware Precision Industries Co., Ltd. (SPIL).
This broadened relationship reflects both companies' commitment to advancing smart factory transformation, environmental monitoring, and sustainability in semiconductor operations.

AIMD

AIMDW

Ainos Expands Strategic Relationship With ASE Technology To Advance Smart Factory Transformation, Environmental Monitoring, And Sustainability In Semiconductor Operations

LSAK

Lesaka Technologies shares are trading higher after the company announced it has agreed to acquire Bank Zero Mutual.

RARE

Ultragenyx Receives FDA Breakthrough Therapy Designation For GTX-102 In Angelman Syndrome

APOG

Apogee Enterprises shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY26 guidance above estimates.

SDGR

Schrödinger Receives FDA Fast Track Designation For SGR-1505 In Relapsed/Refractory Waldenström Macroglobulinemia

Keybanc analyst Noah Zatzkin maintains Acushnet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLF#NYSE">GOLF</a>) with a Overweight and raises the price target from $75 to $80.

GOLF

Keybanc Maintains Overweight on Acushnet Holdings, Raises Price Target to $80

Atlantic Union shares are trading higher after the company announced it closed a $2 billion CRE loan sale to Blackstone.

Guidance

VNET

VNET Raises FY25 Total Net Revenue Growth Guidance From 10-13% To 11-13%, Raises Adj. EBITDA Growth Guidance From 11-14% To 14-16%

Canaccord Genuity analyst George Gianarikas downgrades Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) from Buy to Hold and lowers the price target from $22 to $14.

Downgrades

LYFT

Canaccord Genuity Downgrades Lyft to Hold, Lowers Price Target to $14

Stephens &amp; Co. analyst Terry McEvoy reiterates First Financial Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFBC#NASDAQ">FFBC</a>) with a Overweight and maintains $29 price target.

Reiteration

FFBC

Stephens & Co. Reiterates Overweight on First Financial Bancorp, Maintains $29 Price Target

Integration of high-performing agent-led platform to expand residential real estate and specialty lending footprint&nbsp;
Los Angeles, CA, June 27, 2025 (GLOBE NEWSWIRE) -- OFA Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFAL#NASDAQ">OFAL</a>) ("OFA" or "the Company"), an integrated architecture and technology firm, today announced it has signed a Letter of Intent ("LOI") to acquire a 60% controlling interest in Aspire Homes Realty Inc. and its affiliated lending platform, RateDNA, Inc. ("Acquisitions").
RateDNA is a high-growth, vertically integrated real estate and mortgage business backed by AlphaX, a private investment and development firm based in Orange County, California.&nbsp;Aspire and RateDNA operate a full-service platform serving both residential clients and real estate investors.
Aspire Homes offers brokerage services enhanced by investment-focused agent training and in-house staging, design, and construction. RateDNA complements this with mortgage products tailored to the investor market, including DSCR and non-QM loans, supported by proprietary tools such as the SFR Analytics platform.

OFAL

OFA Group Signs LOI To Acquire 60% Controlling Interest In Aspire Homes Realty And RateDNA; Terms Not Disclosed

Biotech

General

ALLR

Allarity Therapeutics Doses Second Patient In Phase 2 Trial Of Stenoparib For Advanced Ovarian Cancer

LYRA

Lyra Therapeutics Announces Registered Direct Offering Of Up To $15M And Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Canaccord Genuity analyst George Gianarikas downgrades Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) from Buy to Hold and lowers the price target from $90 to $84.

UBER

Canaccord Genuity Downgrades Uber Technologies to Hold, Lowers Price Target to $84

Press Releases

Stevanato Group to Report Third Quarter 2024 Financial Results on November 5, 2024

Stevanato Group Reports Financial Results for the Third Quarter of 2024

Stevanato Group to Present at Upcoming Investor Conferences

Stevanato Group to Present at Upcoming Investor Conference

Stevanato Group to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 6, 2025

Stevanato Group Reports Record Revenue of €1,104 Million for Fiscal Year 2024

Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum

Stevanato Group to Report First Quarter 2025 Financial Results on May 8, 2025

Stevanato Group Reports Revenue of €256.6 Million for the First Quarter of 2025

Stevanato Group to Participate in Upcoming Investor Conferences

STVN

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Stevanato Group

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO